Inspired by rare genetic disease, researchers develop a compound that can protect kidney cells from death and restore kidney function in multiple animal models of progressive kidney disease.
Progressive kidney diseases, whether caused by obesity, hypertension, diabetes, or rare genetic mutations, often have the same outcome: The cells responsible for filtering the blood are destroyed. Reporting today in Science, a team led by researchers from the Broad Institute of MIT and Harvard, Brigham and Women’s Hospital, and Harvard Medical School describes a new approach to prevent death in these essential kidney cells.
Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function. The work, inspired by an investigation into a genetic form of the condition, has the potential to affect therapeutic research for millions of people suffering from progressive kidney diseases.
“We’re ultimately trying to create a drug that can protect these critical filtration cells in the kidney,” said senior author Anna Greka, an institute member at Broad, associate physician at Brigham and Women’s Hospital, and assistant professor at Harvard Medical School. “We attacked the problem from the biology of the genetic disease, and we think we’ve actually found what might be a shared pathway for kidney failure — and a potential way to treat it.”
Treatment options for kidney disease are few and far between, and the last 40 years have seen virtually no progress in new drug development. Patients who receive a transplant often experience complications, and the majority of patients eventually die on dialysis. Of note, the cost of dialysis care in the United States is 50 billion dollars per year, which dwarfs the entire NIH budget.
In order to address this, Greka and her colleagues began their investigation with a rare genetic type of kidney disease, and, using a rat model, set out to understand the genes, proteins, and pathways involved in the organ’s deterioration. The kidney damage is characterized by loss of the filtration cells, or “podocytes,” which normally keep essential proteins in the blood and filter out toxins. When these cells are destroyed, proteins from the blood start spilling out into the urine, a symptom called proteinuria.
Previous work indicated that the genetic mutations in this disease activate a protein called Rac1. Greka’s team revealed that Rac1 then activates a protein called TRPC5 in a damaging feedback loop. In diseased kidneys, TRPC5 causes an influx of calcium ions into the podocyte, eventually destroying it. The researchers designed and tested a variety of compounds to find one that could block this process, and identified a small molecule they called AC1903 (named after Anna Greka and co-author Corey Hopkins of the University of Nebraska Medical Center College of Pharmacy) that looked promising.
In a genetic rat model of progressive kidney disease, AC1903 protected the kidney’s filtration cells. Even when animals began treatment at advanced stages of the disease, AC1903 was able to prevent further podocyte loss and suppress proteinuria, indicating restored kidney function.
“We could literally count the podocytes and see that the cells were preserved with this treatment,” said Greka. “We learned from the genetics, identified the pathway, and then targeted that cellular biology.”
But the team didn’t stop there. The researchers predicted that the TRPC5 mechanism might play a similar role in other types of progressive kidney disease — even if, in those cases, the damaging feedback loop was kickstarted from chronic disorders such as high blood pressure, rather than a specific genetic mutation.
The team tested AC1903 in a rat model of kidney disease caused by hypertension and saw the same results: The treatment preserved kidney podocytes and prevented the organs from failing, even in advanced disease.
The results suggest that TRPC5 channels are activated by a variety of kidney stressors, and that TRPC5 inhibitors may be able to broadly prevent a breakdown of the kidney filter. These compounds may form the basis for much-needed, mechanistically based therapies for progressive kidney diseases.
“Even after we see this rip-roaring, terrible disease that just wreaks havoc on the kidneys, we were able to prevent further damage in these rat models,” said Greka. “Of course, we now need to test TRPC5 inhibitors in clinical studies in patients, but the results are very exciting. The field has waited a very long time — decades, really — for a genetically-inspired, mechanism-based therapy. I’m delighted that our team has contributed to this finally approaching a reality.”
The Latest on: Progressive kidney disease
- Promising treatment does not guard against complication in type 1 diabeteson June 25, 2020 at 7:24 pm
Historically, half or more of people with type 1 diabetes develop kidney disease, which frequently progresses to kidney failure requiring hemodialysis or a kidney transplant for survival.
- Sanofi SA (SNY) CEO Paul Hudson Hosts R&D Day Investor Event (Transcript)on June 25, 2020 at 4:46 pm
R&D Day Investor Event June 23, 2020 09:00 AM ET Company Participants Felix Lauscher - Investor Relations Paul Hudson - CEO John Reed ...
- In Late-Stage Kidney Disease, Urate-Lowering Drug Offers No Helpon June 25, 2020 at 2:07 pm
"Based on preclinical and observational studies, nephrologists have long believed that uric acid plays a causative role in CKD progression and 20% of all CKD patients are prescribed a urate-lowering ...
- Study finds promising treatment to slow kidney disease doesn't prove out in clinical trialon June 25, 2020 at 12:21 pm
Historically, half or more of people with type 1 diabetes develop kidney disease, which frequently progresses to kidney failure, requiring dialysis treatment or kidney transplantation for survival, ...
- Promising treatment to slow kidney disease doesn't prove out in clinical trialon June 25, 2020 at 11:11 am
Progression of kidney disease in type 1 diabetes is correlated with increased amounts of uric acid. A drug that reduces uric acid levels was tested in a multi-institution randomized clinical trial.
- University of Minnesota Medical School finds promising treatment to slow kidney disease doesn't prove out in clinical trialon June 25, 2020 at 11:03 am
A new study from the University of Minnesota Medical School found that allopurinol, an inexpensive generic drug that reduces uric acid levels, did not show benefits in protecting from loss of ...
- Commonly prescribed kidney medication ‘ineffective’: clinical trialon June 24, 2020 at 2:14 pm
Medication prescribed to one in five chronic kidney disease patients is ineffective, a major clinical trial has found. More than ...
- Somatus Raises $64 Million in Series C Financing to Transform Kidney Careon June 24, 2020 at 1:21 pm
Somatus, a market leader in value-based kidney care, today announced it has completed a Series C funding round of $64 million. The funding round was led by Longitude Capital and co-led by Optum ...
- Somatus Lands $64M to Expand Value-Based Kidney Care Modelon June 23, 2020 at 1:37 pm
Somatus raises $64M in Series C funding led by Longitudinal Capital to fuel the expansion of its value-based kidney care model.
- Silicon-based agent could prevent progression of kidney disease and Parkinson’son June 19, 2020 at 4:30 am
Japanese researchers have shown that a silicon-based antioxidant agent can suppress the development of kidney failure and Parkinson's disease in rodents.
via Google News and Bing News